Business
CalciMedica Announces Appointment of Dr. Alan Glicklich to Board of Directors
LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company
About this update from Calcimedica, Inc.
[{"type":"text","content":"LA JOLLA, Calif., Jan. 14, 2025 /PRNewswire/ -- CalciMedica Inc. (\"CalciMedica\" or the \"Company\") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the appointment of Alan Glicklich, M.D. to the Company's Board of Directors effective on January 15, 2025. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics.\n\n \n \n \n \n \n \n\n \n\"We are very pleased to welcome Alan to our Board and excited to benefit from his extensive clinical development experience and impressive track record working with biotech and pharma companies, specifically in the inflammatory and immunologic disease spaces,\" said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. \"As we progress Auxora towards a Phase 3 trial in acute pancreatitis and look ahead to data from our KOURAGE trial in acute kidney injury, Alan's perspective will be extremely valuable to CalciMedica.\"\nIn his position at Nuvig Therapeutics, a company pursuing multiple inflammatory autoimmune diseases, Dr. Glicklich is currently leading a clinical team planning to initiate multiple Phase 2 trials. Prior to Nuvig, Dr. Glicklich was Chief Medical Officer of Chinook Therapeutics, where he was responsible for the clinical development, clinical operations, medical affairs, biometrics, regulatory, and pharmacovigilance teams. While at Chinook, he designed and operationalized a successful Phase 3 registrational study for atrasentan in IgA nephropathy as well as multiple earlier phase studies across rare chronic kidney disease indications. Before that, Dr. Glicklich was Chief Medical Officer at Bird Rock Bio, where he focused on monoclonal antibody development for inflammatory and fibrotic diseases. Prior to Bird Rock, he was Vice President of Clinical Development at Arena Pharmaceuticals, where he designed and operationalized two Phase 2 programs in pulmonary arterial hypertension and ulcerative colitis. Dr. Glicklich has also held positions at BMS, Sanofi-Aventis, and Regeneron. Dr. Glicklich holds an M.D. from the University of Wisconsin and an M.B.A. from the Emory University-Goizueta School of Busi...